Autor(es): Brito, Miguel ; Ginete, Catarina ; Ofakunrin, Akinyemi ; Diaku-Akinwumi, Ijeoma ; Inusa, Baba Psalm
Data: 2025
Identificador Persistente: http://hdl.handle.net/10400.21/21909
Origem: Repositório Científico do Instituto Politécnico de Lisboa
Assunto(s): Sickle cell disease; Sub-Saharan Africa; Anemia; Antimalarial prophylaxis; Blood transfusion; Genetic counseling; Health financing; Hydroxyurea; Malaria prophylaxis; Newborn screening; Penicillin V
Introduction: The management of Sickle cell disease (SCD) in sub-Saharan Africa (SSA) suffers from the lack of universal infant and population screening, inadequate access to standard treatment, and poor public health prioritization amidst unstable political systems. Areas covered: The state of evidence-based management of SCD in SSA was investigated, including the sustainability of international funding agencies. Expert opinion: Current efforts are fragmentary along language lines; sometimes driven by the funder's objectives and not the national agenda. The review highlighted the role of internal and external partnerships, such as SPARCO, ARISE, and CONSA, as well as technology-based support for the implementation of evidence-based care for SCD. We advocate for increased funding to implement SCD comprehensive care in line with the WHO SCD Framework for Primary, Secondary, Tertiary, and Specialist Comprehensive Care at the state and national level. To achieve this objective, it is important that SCD, as a leading non-communicable disease in Africa, be mandated as a standing agenda for the National Council of Ministers at the African Union, the WHO, and other regional bodies in Africa.
